Jagsonpal Pharmaceuticals Limited (JAGSNPHARM) — share transfer

📢 Key Event
Certificate issued for quarter ended June 30, 2026

💡 Investor Takeaway
The filing confirms routine compliance with SEBI transfer rules, with no material changes or future expectations disclosed.

Jagsonpal Pharmaceuticals received a SEBI-mandated certificate from MCS Share Transfer Agent confirming dematerialized securities were listed and transferred within 15 days for the quarter ended June 30, 2026, as required under Regulation 74(5).

📄 View Original Announcement (PDF)

📊 Stock Analysis — JAGSNPHARM ✨ Ask AI About This

About Jagsonpal Pharmaceuticals Limited (JAGSNPHARM)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹1,384.48 Cr P/E: 32.1

View full JAGSNPHARM stock details →

📡 Get AI alerts when JAGSNPHARM files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track JAGSNPHARM — Free

💡 Ask AI about this filing

"How does this affect JAGSNPHARM margins?" "Compare with last quarter results" "What should investors watch for?"

Ask AI Free →

📊 More JAGSNPHARM filings

See all JAGSNPHARM filings →

🔥 Also filed on 6 July 2026

SALSTEEL S.A.L. Steel Limited Announcement RAMASTEEL Rama Steel Tubes Limited Announcement CHAMBLFERT Chambal Fertilizers & Chemicals Limited Announcement LOKESHMACH Lokesh Machines Limited Announcement ASTRON Astron Paper & Board Mill Limited Announcement HEXT Hexaware Technologies Limited Announcement

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

📡 Get AI alerts when JAGSNPHARM files new disclosures

Track JAGSNPHARM filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track JAGSNPHARM — Free

Free account · 2 AI queries/day